Outstanding results from CLARITY: a new CLL combination therapy

Outstanding results from CLARITY: a new CLL combination therapy

VJHemOnc

1 year
104 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The CLARITY study (ISCRTN13751862) is the first clinical trial looking at the combination of venetoclax and ibrutinib for treating relapsed/refractory chronic lymphocytic leukemia (CLL). Here, Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from the University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the promising results, including a response to treatment in all patients, with a significant proportion showing no detectable minimal residual disease (MRD) after 6 months of combination therapy. Prof. Hillmen touches on the steps going forward, such as investigating the combination in Phase III studies and eventually the aim of earlier use in the treatment timeline in order to reach MRD negativity. This video was recorded at the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK.
Up Next Autoplay
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
0 Views
cancernewsupdate 3 minutes
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 27 minutes
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 30 minutes
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Category: General
1 Views
ash 12 hours
Safety and Effectiveness of Apixaban #ASH19
Safety and Effectiveness of Apixaban #ASH19
Category: General
1 Views
ash 13 hours
Brentuximab Vedotin with Chemotherapy #ASH19
Brentuximab Vedotin with Chemotherapy #ASH19
Category: Chronic Myelogenous Leukemia
0 Views
ash 19 hours
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
Category: Chronic Lymphocytic Leukemia
4 Views
ash 21 hours
SWAY Study @LevineCancer #ASH19
SWAY Study @LevineCancer #ASH19
Category: Chronic Lymphocytic Leukemia
0 Views
ash 22 hours
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
ash 23 hours
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
ash 23 hours